Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Segment Operating Expenses Including Segment Expenses, and Net Loss

The Company's reportable segment total operating expenses, including significant segment expenses, and net loss for the years ended December 31, 2024 and 2023, consisted of the following (in thousands):

	Therapeutics
	Year Ended December 31,
	2024			2023
Operating expenses:
Payroll and related	$	48,843		$	28,878
Direct research and development - clinical trials		32,279			19,611
Direct research and development - contract manufacturing		50,753			35,049
Depreciation and amortization		105			22
Other segment items*		35,190			18,452
Total operating expenses		167,170			102,012
Loss from operations		(167,170	)		(102,012	)
Other income (expense):
Interest income		20,714			7,979
Interest expense		(7,626	)		(3,786	)
Other segment items**		1,935			1,830
Loss before provision for income taxes		(152,147	)		(95,989	)
Provision for income taxes		(1	)		(1	)
Segment and consolidated net loss	$	(152,148	)	$	(95,990	)
Other Significant Items:
Expenditures for additions to long-lived assets	$	(972	)	$	(63	)

*Other segment items included in total operating expenses primarily consist of consulting and contractors, professional services, equipment and software, travel and entertainment, facilities, medical affairs, commercial planning, and corporate communications.

**Other segment items included in loss before provision for income taxes consist of currency exchange gains and losses and other income/expense.

Schedule of Reportable Segment Assets

The Company's reportable segment assets consisted of the following (in thousands):

	Therapeutics
	December 31,
	2024		2023
Total segment assets	$	655,681	$	175,546
Total consolidated assets	$	655,681	$	175,546